TX000045

Phase 2Small molecule

TTectonic Operating Company, Inc.

TX000045 is one of 5 small molecule programs targeting Hypertension, Pulmonary. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypertension, PulmonaryRecruiting

Hypertension, PulmonaryPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Hypertension, Pulmonary

#DrugCompanyPhaseTrials

Adempas

Bayer

Phase 3

2 2

Uptravi

Johnson & Johnson

Phase 3

2 3

Opsumit

Johnson & Johnson

Phase 3

1 4

Winrevair

Merck & Co.

Phase 2

1 5

TX000045

TTectonic Operating Company, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Hypertension, Pulmonary

NCT07473700

Clinical

Trials by Indication[1]

Hypertension, Pulmonary1 trial

An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

Recruiting·TTectonic Operating Company, Inc.·Phase 2·NCT07473700·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TX000045. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TX000045 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TX000045. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tectonic Operating Company, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTectonic Operating Company, Inc.

TX000045

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hypertension, Pulmonary1 trial

References

Drug Info

Quick Facts

Related News